Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor

International Journal of Cancer

Volumn 129, Issue 5, 2011, Pages 1116-1125

  Orengo, Anna Maria ^a   Fabbi, Marina ^a   Miglietta, Loredana ^a   Andreani, Cristian ^a   Bruzzone, Milena ^a   Puppo, Andrea ^a   Cristoforoni, Paolo ^a   Centurioni, Maria Grazia ^a   Gualco, Marina ^a   Salvi, Sandra ^a   Boccardo, Simona ^a   Truini, Mauro ^a   Piazza, Tiziana ^a   Canevari, Silvana ^b   Mezzanzanica, Delia ^b   Ferrini, Silvano ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

biomarker; IL 18; immature precursor; ovarian cancer

Indexed keywords

INTERLEUKIN 18; MONOCLONAL ANTIBODY;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; ASCITES FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; EPITHELIUM CELL; FEMALE; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; LYMPHOID CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROLOGY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ASCITIC FLUID; BLOTTING, WESTERN; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTERFERON-GAMMA; INTERLEUKIN-18; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79959690793     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25757     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Martin LP, Schilder RJ,. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 2009; 36: 112-25.
3. Modugno F,. Ovarian cancer and high-risk women symposium presenters. Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 2003; 91: 15-31. (Pubitemid 37203405)
4. Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, Remmenga S, Batra SK,. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 2008; 9: 1076-85.
5. Clarke-Pearson DL,. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361: 170-7.
6. Sasaroli D, Coukos G, Scholler N,. Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med 2009; 3: 275-88.
7. Melnikov A, Scholtens D, Godwin A, Levenson V,. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn 2009; 11: 60-5.
8. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM,. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006; 118: 1750-8. (Pubitemid 43376439)
9. Dinarello CA,. IL-18: a Th1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103: 11-24. (Pubitemid 29063184)
10. Gardella S, Andrei C, Poggi A, Zocchi MR, Rubartelli A,. Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Lett 2000; 481: 245-8.
11. Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW,. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol 1999; 113: 766-72.
12. Sugawara S, Uehara A, Nochi T, Yamaguchi T, Ueda H, Sugiyama A, Hanzawa K, Kumagai K, Okamura H,. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 2001; 167: 6568-75. (Pubitemid 33081593)
13. Kalina U, Ballas K, Koyama N, Kauschat D, Miething C, Arnemann J, Martin H, Hoelzer D, Ottmann OG,. Genomic organization and regulation of the human interleukin-18 gene. Scand J Immunol 2000; 52: 525-30. (Pubitemid 32011763)
14. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mezzanzanica D, Canevari S, Ferrini S,. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer 2002; 98: 873-8. (Pubitemid 34286683)
15. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997; 386: 619-23. (Pubitemid 27175429)
16. Nakanishi K, Yoshimoto T, Tsutsui H, and, Okamura H,. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423-74. (Pubitemid 32368042)
17. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, et al. Cloning of a new cytokine that induces interferon-gamma. Nature 1995; 378: 88-91.
18. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, et al. Cloning of the c DNA for the human IFN - inducing factor, expression in Escherichia coli and studies on the biologic activities of the protein. J Immunol 1996; 56: 4272-9.
19. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S,. Defective NK cell activity and Th1 response in IL-18-deficent mice. Immunity 1998; 8: 383-90. (Pubitemid 28188898)
20. Heuer JG, McClung CT, Hock RA,. Neuroblastoma cells expressing mature IL-18, but not pro-IL-18, induce a strong and immediate antitumour immune response. J Immunother 1999; 22: 324-35. (Pubitemid 29309965)
21. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006; 12: 4265-73.
22. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y,. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 2006; 12: 4473-7. (Pubitemid 44256332)
23. Martone T, Bellone G, Pagano M, Beatrice F, Palonta F, Emanuelli G, Cortesina G,. Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells. Head Neck 2004; 26: 494-503. (Pubitemid 38702636)
24. Merendino RA, Gangemi S, Ruello A, Bene A, Losi E, Lonbardo G, Purello-Dambrosio F,. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers 2001; 16: 126-9. (Pubitemid 32755130)
25. Günel N, Coskun U, Sancak B, Hasdemir O, Sare M, Bayram O, Celenkoglu G, Ozkan S,. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 2003; 26: 416-21. (Pubitemid 36962090)
26. Asakawa M, Kono H, Amemiya H, Matsuda M, Suzuki T, Maki A, Fujii H,. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 2006; 118: 564-70. (Pubitemid 43076003)
27. Carrascal MT, Mendoza L, Valcárcel M, Salado C, Egilegor E, Tellería N, Vidal-Vanaclocha F, Dinarello CA,. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003; 63: 491-7. (Pubitemid 36152512)
28. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcárcel M, Gallot N, Carrascal T, Egilegor E, Beaskoetxea J, Dinarello CA,. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006; 25: 417-34. (Pubitemid 44922359)
29. Gaggero A, De Ambrosis A, Mezzanzanica D, Piazza T, Rubartelli A, Figini M, Canevari S, Ferrini S,. A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene 2004; 23: 7552-60. (Pubitemid 39389697)
30. Keller M, Rüegg A, Werner S, Beer HD,. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132: 818-31. (Pubitemid 351312798)
31. Lamkanfi M, Dixit VM,. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev 2009; 227: 95-105.
32. Pagès F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, Thiounn N, Cugnenc PH, Fridman WH,. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumour immune surveillance. Int J Cancer 1999; 84: 326-30. (Pubitemid 29256763)
33. Sözen S, Coskun U, Sancak B, Bukan N, Günel N, Tunc L, Bozkirli I,. Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade. Neoplasma 2004; 51: 25-9. (Pubitemid 38250153)
34. Okamoto M, Azuma K, Hoshino T, Imaoka H, Ikeda J, Aizawa H,. Correlation of decreased survival and IL-18 in bone metastasis. Intern Med 2009; 48: 763-73.
35. Laird SM, Tuckerman EM, Li TC,. Cytokine expression in the endometrium of women with implantation failure and recurrent miscarriage. Reprod Biomed Online 2006; 13: 13-23. (Pubitemid 44054841)
36. Akahiro J, Konno R, Ito K, Okamura K, Yaegashi N,. Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma. Int J Clin Oncol 2004; 9: 42-6. (Pubitemid 38470662)
37. Terranova PF, Rice VM,. Review: cytokine involvement in ovarian processes. Am J Reprod Immunol 1997; 37: 50-63. (Pubitemid 27075968)
38. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 454: 436-44.
39. Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, Wilkens LR, Tung KH, Ness RB, Goodman MT,. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 2004; 95: 672-9. (Pubitemid 39592536)
40. Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WM,. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998; 101: 1441-52. (Pubitemid 28145262)
41. Clark S, McGuckin MA, Hurst T, Ward BG,. Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines. Cancer Immunol Immunother 1994; 39: 100-4. (Pubitemid 24230193)
42. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C,. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000; 82: 1138-44. (Pubitemid 30128869)
43. Colombo N, Peccatori F, Paganin C, Bini S, Brandely M, Mangioni C, Mantovani A, Allavena P,. Immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 1992; 51: 42-6.
44. Dinarello CA, Novick D, Rubinstein M, Lonnemann G,. Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure. Blood Purif 2003; 21: 258-70. Review. (Pubitemid 36649376)
45. Fairbanks F, Abrão MS, Podgaec S, Dias JA, Jr, de Oliveira RM, Rizzo LV,. Interleukin-12 but not interleukin-18 is associated with severe endometriosis. Fertil Steril 2009; 91: 320-4.
46. Oku H, Tsuji Y, Kashiwamura SI, Adachi S, Kubota A, Okamura H, Koyama K,. Role of IL-18 in pathogenesis of endometriosis. Hum Reprod 2004; 19: 709-14. (Pubitemid 38344538)
47. Arici A, Matalliotakis I, Goumenou A, Koumantakis G, Vassiliadis S, Mahutte NG,. Altered expression of interleukin-18 in the peritoneal fluid of women with endometriosis. Fertil Steril 2003; 80: 889-94. (Pubitemid 37230023)